Current Report Filing (8-k)
31 Enero 2019 - 3:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 25, 2019
CYTOMX THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-37587
|
|
27-3521219
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
151 Oyster Point Blvd.
Suite 400
South San
Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650)
515-3185
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
Compensatory Arrangements of Certain Officers
On January 25, 2019, the Compensation Committee of the Board of Directors (the Board) of CytomX Therapeutics, Inc. (the
Company) approved: (a) annual base salaries for 2019 and (b) cash performance bonuses for 2018 for the following principal financial officer and named executive officers of the Company:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Current Position
|
|
Salary
Increase
(%)
|
|
Salary
Increase
($)
|
|
2019
Base
Salary
|
|
2018
Cash
Bonus
|
Debanjan Ray, Chief Financial Officer
|
|
|
|
4.0
|
%
|
|
|
$
|
15,750
|
|
|
|
$
|
409,500
|
|
|
|
$
|
196,875
|
|
Rachel W. Humphrey, M.D., Chief Medical Officer
|
|
|
|
4.0
|
%
|
|
|
$
|
17,617
|
|
|
|
$
|
458,065
|
|
|
|
$
|
220,224
|
|
W. Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and
Non-Clinical
Development
|
|
|
|
4.0
|
%
|
|
|
$
|
17,094
|
|
|
|
$
|
444,451
|
|
|
|
$
|
213,678
|
|
On January 25, 2019, the Board approved the annual base salary for 2019 and cash performance bonus for
2018 for the following principal executive officer:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Current Position
|
|
Salary
Increase
(%)
|
|
Salary
Increase
($)
|
|
2019
Base
Salary
|
|
2018
Cash
Bonus
|
Sean A. McCarthy, D. Phil., President, Chief Executive Officer and Chairman
|
|
|
|
4.5
|
%
|
|
|
$
|
25,000
|
|
|
|
$
|
575,000
|
|
|
|
$
|
412,500
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 31, 2019
|
|
|
|
CYTOMX THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lloyd Rowland
|
|
|
|
|
|
|
Lloyd Rowland
|
|
|
|
|
|
|
SVP, General Counsel
|
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024